Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action

21 Oct 2016

Creek, Darren J.; Chua, Hwa H.; Cobbold, Simon A.; Nijagal, Brunda; MacRae, James I.; Dickerman, Benjamin K.; Gilson, Paul R.; Ralph, Stuart A.; McConville, Malcolm J.

Antimicrobial Agents and Chemotherapy

doi: 10.1128/AAC.01226-16


High-throughput phenotypic screening of chemical libraries has resulted in the identification of thousands of compounds with potent antimalarial activity, although in most cases, the mechanism(s) of action of these compounds remain unknown. Here we have investigated the mode of action of 90 antimalarial compounds derived from the Malaria Box collection using high-coverage, untargeted metabolomics analysis. Approximately half of the tested compounds induced significant metabolic perturbations in in vitro cultures of P. falciparum.

In most cases, the metabolic profiles were highly correlated with known antimalarials, in particular artemisinin, the 4-aminoquinolines, or atovaquone. Select Malaria Box compounds also induced changes in intermediates in essential metabolic pathways such as isoprenoid biosynthesis (i.e. 2-C-methyl-D-erythritol 2,4-cyclodiphosphate), and linolenic acid metabolism (i.e. traumatic acid). This study provides a comprehensive database of the metabolic perturbations induced by chemically diverse inhibitors and highlights the utility of metabolomics for triaging new lead compounds and defining specific modes of action, which will assist with the development and optimization of new antimalarial drugs.

Read the full article on the Antimicrobial Agents and Chemotherapy website.